1. Rafati S., Kamhawi S., Valenzuela, JG, Ghanei M., Building Research and Development Capacity for Neglected Tropical Diseases Impacting Leishmaniasis in the Middle East and North Africa: a Case Study. PLOS NTD, Accepted 2015.

2. Oliveira PR, Dessein H, Romano A, Cabantous S, de Brito ME, Santoro F, Pitta MG, Pereira V, Pontes-de-Carvalho LC, Rodrigues V Jr, Rafati S, Argiro L, Dessein AJ IL2RA genetic variants reduce IL-2-dependent responses and aggravate human cutaneous leishmaniasis..J Immunol. 2015 Mar 15;194(6):2664-72.

3. Golshani M, Rafati S, Dashti A, Gholami E, Siadat SD, Oloomi M, Jafari A, Bouzari S Vaccination with recombinant L7/L12-truncated Omp31 protein induces protection against Brucella infection in BALB/c mice..Mol Immunol. 2015 Jun;65(2):287-92

4. Golshani M, Rafati S, Siadat SD, Nejati-Moheimani M, Shahcheraghi F, Arsang A, Bouzari S Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen..Mol Immunol. 2015 May 8;66(2):384-391

5. Taheri T, Saberi Nik H, Seyed N, Doustdari F, Etemadzadeh MH, Torkashvand F, Rafati S Generation of stable L. major(+EGFP-LUC) and simultaneous comparison between EGFP and luciferase sensitivity.. Exp Parasitol. 2015 Mar;150:44-55

6. Tahereh Taheri, Elham Gholami, Faeze Saatchi, Negar Seyed, Yasaman Taslimi, Sima Rafati. Expressional comparison between episomal and stable transfection of selected tri-fused protein in Leishmania tarentolae. (Vaccine Research, 2014, 1 (1):9.

7. Fotouhi F, Farahmand B, Heidarchi B, Esghaei M, Rafati S, Tavassoti Kheiri M. In Vitro Evaluation of Influenza M2 and Leishmania major HSP70 (221-604) Chimer Protein.
Jundishapur J Microbiol. 2014;7(9):e11812

8. Pishraft Sabet L, Taheri T, Memarnejadian A, Mokhtari Azad T, Asgari F, Rahimnia R, Alavian SM, Rafati S, Samimi Rad K. Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice. Hepat Mon. 2014 Oct 15;14(10).

9. Pishraft-Sabet L, Kosinska AD, Rafati S, Bolhassani A, Taheri T, Memarnejadian A, Alavian SM, Roggendorf M, Samimi-Rad K Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96 Arch Virol. Arch Virol. 2015 Jan;160(1):141-52

10. Negar Seyed, Tahereh Taheri, Charline Vauchy, Magalie Dosset, Yann Godet, Ali Eslamifar, Iraj Sharifi, Olivier Adotevi, Christophe Borg, Pierre Simon Rohrlich, Rafati S,. Immunogenicity Evaluation of a Rationally Designed Polytope Construct Encoding HLA-A*0201 Restricted Epitopes Derived From Leishmania major Related Proteins in HLA-A2/DR1 Transgenic Mice: Steps Toward Polytope Vaccine PLoS One. 2014 Oct 13;9(10):e108848

11. Saljoughian N, Taheri T, Rafati S. Live Vaccination Tactics: Possible Approaches for Controlling Visceral Leishmaniasis. Front Immunol. 31;5:134. 2014. Review.

12. Zahedifard F, Gholami E, Taheri T, Taslimi Y, Doustdari F, Seyed N, Torkashvand F, Meneses C, Papadopoulou B, Kamhawi S, Valenzuela JG, Rafati S. Enhanced protective efficacy of nonpathogenic recombinant Leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen. (PLoS Negl Trop Dis. 27;8(3):e2751. 2014)

13. Taheri T, Rafati S., Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development, Clin. Invest. (2013) 3(11), 1023–1044

14. Dabirian S, Taslimi Y, Zahedifard F, Gholami E, Doustdari F, Motamedirad M, Khatami S, Azadmanesh K, Nylen S, Rafati S., Human neutrophil peptide-1 (HNP-1): a new anti-leishmanial drug candidate. PLoS Negl Trop Dis. 7(10):e2491. 2013.

15. Mohit E, Rafati S. Biological delivery approaches for gene therapy: strategies to potentiate efficacy and enhance specificity. (Molecular Immunology 2013;56(4):599-611 ).

16. Hosseinzadeh S, Bolhassani A, Rafati S, Taheri T, Zahedifard F, Daemi A, Taslimi Y, Hashemi M, Memarnejadian A. A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers. (Drug Deliv. 2013 2013 ;20(3-4):190-8).

17. Saljoughian N, Zahedifard F, Doroud D, Doustdari F, Vasei M, Papadopoulou B, Rafati S. Cationic solid lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. (Parasite Immunol. 2013 35(12):397-408)

18. Saljoughian N, Taheri T, Zahedifard F, TaslimiY, Doustdari F, Doroud D, Azizi H, Heidari K, Vasei M, Namvar N, Papadopoulou B, Rafati S. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. (PLOS Neglected Tropical Diseases. 2013, 18;7(4):e2174)

19. Mohit E, Bolhassani A, Zahedifard F, Seyed N, Eslamifar A, Taghikhani M, Samimirad K Rafati S. Enhancement of DNA vaccine potency by covalent linkage to Gp96, co-administration of IP-10 and PEI600-Tat delivery system against HPV infections. (Mol Immunol. 2013 ,53(1-2):149-60)

20. Bolhassani A, Rafati S. Mini-chaperones: Potential immuno-stimulators in vaccine design.(Hum Vaccin Immunother. 2012 Oct 29;9(1)).

21. Daemi A, Bolhassani A, Rafati S, Zahedifard F, Hosseinzadeh S, Doustdari F Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.(Immunol Lett. 2012 17.: S0165- 2478(12)00215-5)

22. Salehi M, Taheri T, Mohit E, Zahedifard F, Seyed N, Taslimi Y, Sattari M, Bolhassani A, Rafati S. Recombinant Leishmania tarentolae Encoding the Human papillomavirus Type16 E7 Gene in Tumor Mice Model. (Immunotherapy.2012 Nov;4(11):1107-20)

23. Mohit E, Rafati S. Chemokine-based Immunotherapy: Delivery systems and combination therapies, Review ( Immunotherapy. 2012, 4 (8) 1-34)

24. Doroud D, Rafati S. Leishmaniasis:focus on the design of nanoparticulate vaccine delivery systems. (Expert Rev,2012:75(1)27-37)

25. Stäger S, Rafati S. CD8(+) T cells in leishmania infections: friends or foes?(Front Immunol. 2012;3:5)

26. Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S. The Contribution of NT-gp96 as an Adjuvant for Increasing HPV16 E7-Specific Immunity in C57BL 6 Mouse Model.(Scand J Immunol,2012:75(1):27-37)

27. Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery systems for cancer therapy.(Mol Cancer. 2011 Jan 7;10:3)

28. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Rafati S. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL⁄6 mice.(Parasite Immunol. 2011 Jun;33(6):335- 48) .

29. Amani J, Mousavi SL, Rafati S, Salmanian AH. Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice.(Plant Sci. 2011;180(4):620-7) Mizbani A, Taslimi Y, Zahedifard F, Taheri T, Rafati S. Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae.( Parasitol Res, 2011:109(3):793-9)

30. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Taslimi Y, Vahabpour R, Torkashvand F, Vaziri B, Rafati S. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection.(J Control Release, 2011: 30;153(2):154-62) .

31. Doroud D, Zahedifard F, Vatanara A, Taslimi Y, Vahabpour R, Torkashvand F, Vaziri B, RouholaminiNajafabadi A, Rafati S. C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice.(PlosNegl Trop Dis,2011:5(7)1236).

32. Safaiyan S, Bolhassani A, Nylen S, Akuffo H, Rafati S. Contribution of human neutrophils in the development of protective immune response during in vitro Leishmania major infection. (Parasite Immunol, 2011:33(11):609-20).

33. McDowell MA, Rafati S, Ramalho-Ortigao M, Ben Salah A. Leishmaniasis Middle East and North Africa research and development priorities.(PlosNegl Trop Dis,2011:5(7)1219)

34. Mehrizi A.A, Zakeri S, Rafati S, Salmanian A.H, Djadid N.D. Immune responses elicited by co-immunization of Plasmodium vivax and P.falciparum MSP-1 using prime-boost immunization strategies.(ParasiteImmunol,2011:33(11):594-608)

35. Seyed N, Zahedifard F, Safaiyan SH, Gholami E, Doustdari F, Azadmanesh K, Mirzaei M, Eslami N KhademSadegh A, Eslami far A, Sharifi I, Rafati S. In Silico Analysis of Six Known Leishmania major Antigens and In Vitro Evaluation of Specific Epitopes Eliciting HLA-A2 Restricted CD8 T Cell Response.(PlosNegl Trop Dis,2011:5(9)1295)

36. Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against L.major infection in susceptible BALB/c Mice and its antigenic properties in human Leishmania.(Experimental Parasitology, 2011:127(3)627-36)

37. Bolhassani A, Gholami E, Zahedidard F, moradin N, Parsi P, Doustdari F, Papadoulou B Rafati S. Enhancement of DNA vaccine potency by fusion of HSV-1VP22 and EGFP to Leishmania major amastin antigenin BALB/c mice model. (Experimental Parasitology, 2011:128(1):9-17)

38. Bolhassani A, Taheri T, Taslimi Y, Zamanlui S, Zahedifard F, Seyed N, Torkashvand F, Vaziri B Rafati S. Fluorescent Leishmania species: Development of stable GFP xpression and its application for in vitro and in vivo studies. (Experimental Parasitology, 2011:127(3):637-45)

39. Amani J., Salmanian A.H., Rafati S., Mousavi SL. Immunogenic Properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157;H7. (Vaccine, 2010:28(42):6923-9 )

40. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Gholami E, Rafati S. Cationic solid lipid nanoparticles loaded by cysteine proteinase Genes as a Novel anti-leishmaniasis DNA vaccine Delivery system: characterization and in vitro evaluation. (Journal of pharmacy and pharmaceutical science, 2010, 13(3) 320-335)

41. Taheri T., Salmanian A., Gholami E., Doustdari F., Zahedifard F., Rafati S. Disruption of Leishmania major signal peptidase type I and its consequences in survival, growth and infectivity rate of parasite. (Experimental Parasitology, 2010 (126)135-145)

42. Mizbani A., Taheri T., Zahedifard F., Taslimi Y., Azizi H., Azadmanesh K., Papadoulou B., Rafati S. Recambinant Leishmania tarentolae expressing the A2 Virulence gene as a novel candidate Vaccine against Visceral Leishmaniasis. (Vaccine 28 (2010) 53-62)

43. Bolhassani A., Zahedifard F., Taslimi Y., Taghikhani. M, Nahavandian B., Rafati S. Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients. (Indian J Med Res. 2009 Nov;130(5):533-41)

44. Arashkia A., Roohvand F., Memarnejadian A., Aghasadeghi MR., Rafati S. Construction of HCV-polytope vaccine candidates harboring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice.(Virus Genes. 2010 40(1):44-52)

45. Amani J., Mousavi SL., Rafati S. Salmanian A.H., In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications. (TheorBiol Med Model. 2009 ;8;6:28)

46. Bolhassani A., Mohit E., Rafati S. Different spectra of therapeutic vaccine development against HPV infections.( Human Vaccines2009, 5:10, 1-18)

47. Bolhassani A. and Rafati S. DNA Immunization as an Efficient Strategy for Vaccination. (Avicenna Journal of Medical Biotechnology, 2009 vol.1, No2)

48. Azizi H., Hassani K.,Taslimi Y., ShateriNajafabadi H., Papadopoulou B., Rafati S. Searching for virulence factors in the non-pathogenic parasite to humans Leishmania tarentolae. (Parasitology, 2009; 136: 723-735)

49. Bolhassani A., Ghasemi N., Servis C., Taghikhani M. and Rafati S. The Efficiency of a Novel Delivery System (PEI600-Tat) in Development of Potent DNA Vaccine Using HPV16 E7 as a Model Antigen. (Drug Delivery, 2009; 16(4):196-204)

50. Salhi A, Rodrigues, Santoro F, Dessein H, Romano A, Castellano L.R, Mathieu Sertorio, Rafati S, Chevillard C, Prata A, Alcaı¨s, Laurent Argiro A, Dessein A. Immunological and Genetic Evidence for a Crucial Role of IL-10 in Cutaneous Lesions in Humans Infected with Leishmania braziliensis. (J. Immunology, 2008; 180(9):6139-48.

51. Bolhassani A., Taghikhani M., Ghasemi N., Soleimanjahi H., Rafati S. Comparison of Two Delivery Systems Efficiency by Using Poly ethylenimine (PEI) for Plasmid HPV16E7 DNA Transfection into COS-7 Cells. (Modarres Journal of Medical Sciences, 2008 Vol.11, No 1&2)

52. Memarnejadian A., Roohvand F., Arashkia A., Rafati S., Shokrgozar MA., Polytope DNA vaccine development against hepatitis C virus: A stream-lined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. (Protein & peptide letters, 2009 16(7):842-50)

53. Bolhassani A., Rafati S. Heat-shock proteins as powerful weapons in vaccine development. (Expert Rev Vaccines, 2008; 7(8):1185-99, Review)

54. Abtahi H., Salmanian A.H., Rafati S., Nejad GB., Saffari M., Ghazavi A., Mosayebi G. The profile of cytokines and IgG subclasses in BALB/c mice after immunization with Brucella ribosomal gene. (Pak J BiolSci, 2008;11(21): 2472-7)

55. Bolhassani A., Zahedifard F., Taghikhani M., Rafati S. Enhanced immunogenecity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.( Vaccine ,2008; 26(46):5822-9)

56. Rafati S., Zahedifard F., KakehAzari M., Taslimi Y., Taheri T. C-terminal Extension of cysteine proteinase type I is responsible for TH2 elicitation in experimental murine L. infantum infection. (Experimental Parasitology, 2008;118: 393-401)

57. Golkar M., Rafati S., Abdel-Latif MS., Brenier-Pinchart MP., Fricker-Hidalgo H., Sima BK., Babaie J., Pelloux H., Cesbron-Delauw MF., Mercier C. The dense granule protein GRA2, a new marker for the serodiagnosis of acute Toxoplasma infection: comparison of sera collected in both France and Iran from pregnant women. (DiagnMicrobiol Infect Dis, 2007;58(4):419-26)

58. Golkar M., Shokrgozar MA., Rafati S., Musset K., Assmar M., Sadaie R., Cesbron-Delauw MF. andMercier C. Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice. (Vaccine,2007;25 (21):4301-11)

59. Balenga NA., Rafati S. Innate immune system: Specific or non-specific?
(Med Hypotheses,2007;69(2):460-1)

60. Rafati S., Gholami E., Hassani N., Ghaemimanesh F., Taslimi Y., Taheri T., Soong L. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. (Vaccine, 2007;25(21) :4159-69)

61. Rafati S., Hassani N., Taslimi Y., Movassagh H., Rochette A., Papadopoulou B. Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis. (Clin Vaccine Immunol, 2006;13(10):1104-10)

62. Khamesipour A., Rafati S., Davoudi N., Maboudi F., Modabber F. Leishmaniasis vaccine candidates for development: a global overview. (Indian J Med Res,2006;123(3):423-38. Review)

63. Balenga NA., Zahedifard F., Weiss R., Sarbolouki MN., Thalhamer J., Rafati S. Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy.(J Biotechnol, 2006;124(3):602-14)

64. Rafati S., Ghaemimanesh F., Zahedifard F. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice. (Vaccine, 2006;24(16):3290-7)

65. Rafati S., Zahedifard F., Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. (Vaccine, 2006;24(12):2169-75)

66. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., Sanos S., Kaye P., Taghikhani M., Jamshidi S. andRad MA. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. (Vaccine, 2005;23(28):3716-25)

67. Nakhaee A., Rafati S., Salmanian A.H., Taghikhani M., Mohebali M., Taheri T. Immunological responses of naturally infected dogs to Type I and Type II recombinant cysteine proteinases of Leishmaniainfantum.(Moddares J. of Medical Sciences, 2005;8(1):55-66)

68. Golkar M., Shokrgozar M.A., Rafati S., Sadaie M.R., and Assmar M. Construction, expression and preliminary immunological evaluation of a DNA plasmid encoding the GRA2 protein of Toxoplasma gondii.(Iranian Biomedical Journal,2005;9(1):1-8)

69. Rafati S., Salmanian A.H., Taheri T., Masina S., Schaff C., Taslimi Y. andFasel N. Type I signal peptidase from Leishmania is a target of the immune response in human cutaneous and visceral leishmaniasis.(MolBiochemParasitol,(2004; 135(1):13-20)

70. Zadeh-Vakili A., Taheri T., Taslimi Y., Doustdari F., Salmanian A.H. andRafati S. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.(Vaccine,2004;22(15-16):1930-40)

71. Zadeh-Vakili A., Taheri T., Taslimi Y., Doutdari F., Salmanian A.H., Rafati S. Bivalent DNA vaccination with genes encoding Leishmania major cysteine proteinases type I and type II protects mice against infectious challenge. (Iranian Journal of Biotechnology, 2004;2(1):10-15)

72. Nakhaee A., Taheri T., Taghikhani M., Mohebali M., Salmanian A.H., Fasel N., Rafati S. Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population.(Vet Parasitol,2004;119(2-3):107-23)

73. Abtahi H., Salmanian AH., Rafati S., BehzadianNejad G. Hassan ZM. High level expression of recombinant ribosomal protein (L7/L12) from Brucellaabortus and its reaction with infected human sera. (Iranian Biochemical Journal 2004;8(1): 13-18)

74. Golkar M., Rafati S., TaslimiY, Taheri T. Doustdary F. andAssmar M. High-level expression and evaluation the M. High-level expression and evaluation the antigenicity of a recombinant Toxoplasma gondii GRA2 protein. (Iranian Journal of Biotechnology, 2004;2(3))

75. Rafati S., Fasel N. Masina S. Leishmania cysteine proteinases: from gene to putative subunit vaccine.( Review, Current Genomic. 2003; 4:109-121)

76. Mahmoodi M., Khamesipour A., Dowlati Y., Rafati S., Momeni AZ., Emamjomeh M., Hejazi H. andModabber F. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. (ClinExpImmunol. 2003;134(2):303-8)

77. Rafati S., Nakhaee A., Taheri T., Ghashghaii A., Salmanian AH., Jimenez M., Mohebali M., Masina S. andFasel N. Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis.( ExpParasitol.2003;103(3-4):143-51)

78. Pascalis H., Lavergne A., Bourreau E., Prévot-Linguet G., Kariminia A., Pradinaud R., Rafati S. and Launois P. Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis. (Infect Immun. 2003;71(5):2924-6)

79. Farzaneh P., Ebtekar M., Hassan ZM. andRafati S. Murine cytokine patterns following rubella vaccination. (Iran J Allergy Asthma Immunol. 2003;2(2):89-93)

80. Rafati S., Kariminia A., Seyde-Eslami S., Narimani M., Taheri T. Lebbatard M. Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation. (Vaccine. 2002;20(19-20):2439-47)

81. Rafati S., Salmanian A.H., Taheri T., Vafa M. and Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major.(Vaccine. 2001;19(25-26):3369-75)

82. Rafati S., Salmanian A.H., Hashemi K., Schaff C., Belli S. Fasel N. Identification of Leishmania major cysteine proteinases as targets of the immune response in humans. (MolBiochemParasitol, (2001;113(1):35-43)

83. Rafati S., Abraham Baba A., Bakhshayesh M. andVafa M. Vaccination of BALB/c mice with Leishmania majoramastigote-specific cysteine proteinase.(ClinExpImmunol. 2000;120(1):134-8)

84. Solioz N., Blum-Tirouvanziam U., Jacquet R., Rafati S., Corradin G., Mauël J. Fasel N. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis. (Vaccine. 1999;18(9-10):850-9)

85. Rafati S., Couty-Jouve S.,Alimohammadian M.H. Louis JA. Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis. (ClinExpImmunol. 1997;110(2):203-11)

86. Rafati S., Couty-Jouv S., Dowlati Y. and Alimohammadian M.H. Evaluation of cellular immune responses of recovered human cutaneous leishmaniasis to amastigote soluble L. major antigen. (Medical Journal of the Islamic Republic of Iran. 1997;11(1):33-38)